Determinants of cytotoxicity with prolonged exposure to fluorouracil in human colon cancer cells

Oncology Research

Volumn 9, Issue 2, 1997, Pages 77-88

  Ren, Qianfang ^a   Van Groeningen, Cornelius J ^a   Hardcastle, Anthea ^a   Wynne Aherrie, G ^a   Geoffroy, Francois ^a   Allègra, Carmen J ^a   Johnston, Patrick G ^a   Grem, Jean L ^a  

^a Division of Clinical Sciences   (United States)

Author keywords

Colon cancer; Dna damage; Fluorouracil; Thymidylate synthase

Indexed keywords

5 FLUORO 2' DEOXYURIDINE 5' DIPHOSPHATE; 5-FLUORO-2'-DEOXYURIDINE-5'-DIPHOSPHATE; 5-FLUOROURIDINE 5'-TRIPHOSPHATE; DEOXYRIBONUCLEOTIDE; DEOXYURIDINE PHOSPHATE; DNA; DRUG DERIVATIVE; FLOXURIDINE PHOSPHATE; FLUOROURACIL; FLUOROURIDINE TRIPHOSPHATE; FOLINIC ACID; THYMIDYLATE SYNTHASE; URIDINE TRIPHOSPHATE;

ARTICLE; BIOSYNTHESIS; CELL CULTURE; CELL DIVISION; CELL SURVIVAL; COLON TUMOR; DNA DAMAGE; DOSE RESPONSE; DRUG ANTAGONISM; DRUG EFFECT; GENE EXPRESSION REGULATION; HUMAN; METABOLISM;

CELL DIVISION; CELL SURVIVAL; COLONIC NEOPLASMS; DEOXYRIBONUCLEOTIDES; DEOXYURACIL NUCLEOTIDES; DNA DAMAGE; DNA, NEOPLASM; DOSE-RESPONSE RELATIONSHIP, DRUG; FLUORODEOXYURIDYLATE; FLUOROURACIL; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HUMANS; LEUCOVORIN; THYMIDYLATE SYNTHASE; TUMOR CELLS, CULTURED; URIDINE TRIPHOSPHATE;

EID: 0030626746     PISSN: 09650407     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (57)

1. Grem, J. L. 5-Fluoropyrimidines. In: Chabner, B. A.; Longo, D. L., eds. Cancer chemotherapy and biotherapy, 2nd ed. Philadelphia: Lippincott Co.; 1996:149-211.
2. Evans, R. M.; Laskin, J. D.; Hakala, M. T. Assessment of growth-limiting events caused by 5-fluorouracil in mouse cells and in human cells. Cancer Res. 40:4113-4122; 1980.
3. Spears, C. P.; Shani, J.; Shahinian, A. H.; Wolf, W.; Heidelberger, C.; Danenberg, P. V. Assay and time course of 5fluorouracil incorporation into RNA of L1210/0 ascites cells in vivo. Mol. Pharmacol. 27:302-307; 1984.
4. Calabro-Jones, P. M.; Byfield, J. E.; Ward, J. F.; Sharp, T. R. Time-dose relationships for 5-fluorouracil cytotoxicity against human epithelial cancer cells in vitro. Cancer Res. 42: 4413-4420; 1982.
5. Drewinko, Y. L-Y. Cellular basis for the inefficacy of 5-FU in human colon carcinoma. Cancer Treat. Rep. 69:1391-1398; 1985.
6. Santelli, G.; Valeriote, F. Schedule-dependant cytotoxicity of 5-fluorouracil in mice. J. Natl. Cancer Inst. 76:159-164; 1986.
7. Moran, R. G.; Scanion, K. L. Schedule-dependent enhancement of the cytotoxicity of fluoropyrimidines to human carcinoma cells in the presence of folinic acid. Cancer Res. 51: 4618-4623; 1991.
8. Aschele, C.; Sobrero, A.; Faderan, M. A.; Bertino, J. R. Novel mechanisms of resistance to 5-fluorouracil in human colon cancer (HCT-8) sublines following exposure to two different clinically relevant dose schedules. Cancer Res. 52:18551864;1992.
9. Erlichman, C.; Fine, S.; Elhakim, T. Plasma pharmacokinetics of 5-FU given by continuous infusion with allopurinol. Cancer Treat. Rep. 70:903-904; 1986.
10. Thyss, A.; Milano, G.; Renée, N.; Vallidoni, J.; Schneider, M.; Demard, F. Clinical pharmacokinetic study of 5-FU in continuous 5-day infusions for head and neck cancer. Cancer Chemother. Pharmacol. 16:64-66; 1986.
11. Harris, B. E.; Song, R.; Soong, S-J.; Diasio, R. B. Relationship between dihydropyrimidine dehydrogenase activity and plasma 5-fluorouracil levels with evidence for circadian variation of enzyme activity and plasma drug levels in cancer patients receiving 5-fluorouracil by protracted continuous infusion. Cancer Res. 50:197-201; 1990.
12. Grem, J. L.; McAtee, N.; Baus, F.; Murphy, R.; Venzon, D.; Kramer, B.; Goldspiel, B.; Begley, M.; Allegra, C. J. A phase II study of continuous infusion 5-fluorouracil and leucoyorin with weekly cisplatin in metastatic colorectal carcinoma. Cancer 72:663-668; 1993.
13. Yoshida, T.; Araki, E.; ligo, M.; Fujii, T.; Yoshino, M.; Shimada, Y.; Daito, D.; Tajari, H.; Yamaguchi, H.; Yoshida, S.; Yoshino, M.; Ohkura, H.; Yoshimori, M.; Okazaki, N. Clinical significance of monitoring serum levels of 5fluorouracil by continuous infusion in patients with advanced colonie cancer. Cancer Chemother. Pharmacol. 26:352-354; 1990.
14. Anderson, L. W.; Parker, R. J.; Collins, J. M.; Ahlgren, J. D.; Wilkinson, D.; Strong, J. M. Gas chromatographic-mass spectrometric method for routine monitoring of 5-fluorouracil in plasma of patients receiving low-level protracted infusions. J. Chromatogr. 581:195-201; 1992.
15. Kish, J. A.; Ensley, J. F.; Jacobs, J.; Weaver, A.; Cummings, G.; Al-sarraf, M. A randomized trial of cisplatin plus 5fluorouracil infusion and cisplatin plus 5-FU bolus for recurrent and advanced squamous cell carcinoma of the head and neck. Cancer 56:2740-2744; 1985.
16. Lokich, J. J.; Ahlgren, J. D.; Gullo, J. J.; Philips, J. A.; Fryer, J. G. A prospective randomized comparison of continuous infusion fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma. A Mid-Atlantic Oncology Program Study. J. Clin. Oncol. 7:425-432; 1989.
17. O'Connell, M. J.; Martenson, J. A.; Wieand, H. S.; Krook, J. E.; Macdonald, J. S.; Haller, D. G.; Mayer, R. J.; Gunderson, L. L.; Rieh, T. A. Improving adjuvant therapy for rectal cancer by combining protracted infusion fluorouracil with radiation therapy after curative surgery. N. Engl. J. Med. 331: 502-507; 1994.
18. Crem, J. L.; Fischer, P. H. Alteration of fluorouracil metabolism in human colon cancer cells with a selective increase in fluorodeoxyurîdine monophosphate levels. Cancer Res. 46: 6191-6199; 1986.
19. Geoffroy, F.; Allegra, C. J.; Grem, J. L. Enhanced cytotoxicity with interleukin-la and 5-fluorouracil in HCT 116 colon cancer cells. Oncol. Res. 6:581-591; 1994.
20. Yee, L. K.; Allegra, C. J.; Steinberg, S. M.; Grem, J. L. Decreased catabolism of 5-fluorouracil in peripheral blood mononuclear cells during therapy with 5-fluorouracil, leucovorin, and Interferon a-2a. J. Natl. Cancer Inst. 84:18201825; 1992.
21. Grem, J. L.; Geoffroy, F.; Politi, P.; Cuddy, D.; Ross, D. D.; Nguyen, D.; Allegra, C. J. Determinants of sensitivity to 1-0-D-arabinofuranosyIcytosine in human colon carcinoma cell lines. Mol. Pharmacol. 48:305-315; 1995.
22. Miller, S. A.; Dykes, D. D.; Polesky, H. F. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res. 16:1215; 1988.
23. Piall, E. M.; Curtin, N. J.; Aherne, G. W.; Harris, A. L.; Marks, V. The quantitation by radioimmunoassay of 2'deoxyuridine 5'-triphosphate in extracts of thymidylate synthase-inhibited cells. Anal. Biochem. 177:347-352; 1989.
24. Aherne, G. W.; Hardcastle, A.; Raunaud, F.; Jackman, A. L. Immunoreactive dUMP and TTP pools as an index of thymidylate synthase inhibition; effect of tomudex (ZD1694) and a nonpolyglutamated quinazoline antifolate (CB30900) in L1210 mouse leukemia cells. Biochem. Pharmacol. 51:12931301; 1996.
25. Allegra, C. J.; Chabner, B. A.; Drake, J. C.; Lutz, R.; Rodbard, D.; Jolivet, J. Enhanced inhibition of thymidylate synthase by methotrexate polyglutamates. J. Biol. Chem. 260: 9720-9726;1985.
26. Grem, J. L.; Voeller, D. M.; Geoffroy, F.; Horak, E.; Johnston, P. G.; Allegra, C. J. Determinants of trimetrexate lethality in human colon cancer cells. Br. J. Cancer 70:10751084; 1994.
27. Johnston, P. G.; Liang, C-M.; Henry, S.; Chabner, B. A.; Allegra, C. J. Production and characterization of monoclonal antibodies that localize human thymidylate synthase in the cytoplasm of human cells and tissue. Cancer Res. 51:66886676; 1991.
28. Johnston, P. G.; Drake, J. C.; Trepel, J.; Allegra, C. J. Immunological quantitation of thymidylate synthase using the monoclonal antibody TS106 in 5-fluorouracil-sensitive and -resistant human cancer cell lines. Cancer Res. 52:4306-4312; 1992.
29. Ross, E. D.; Chen, S-R. S.; Cuddy, D. P. Effects of 1-0arabinofuranosylcytosine on DNA replication intermediates monitored by pH-step alkaline elution. Cancer Res. 50:26582666; 1990.
30. Kohn, K. W.; Ewig, R. A. C.; Erickson, L. C.; Zwelling, L. A. Measurement of strand breaks and cross-links by alkaline elution. In: Friedberg, E. C.; Hanawalt, P. C., eds. DNA repair. A laboratory manual of research procedures. New York: Marcel Dekker; 1981:379-401.
31. Bertrand, R.; Sarang, M.; Jenkin, J.; Kerrigan, D.; Pommier, Y. Differential induction of secondary DNA fragmentation by topoisomerase II inhibitors in human tumor cell lines with amplified C-myc expression. Cancer Res. 51:6280-6285; 1991.
32. Grem, J. L.; Fischer, P. H. Augmentation of 5-fluorouracil cytotoxicity in human colon cancer cells by dipyridamole. Cancer Res. 45:2967-2972; 1985.
33. Canman, C. E.; Lawrence, T. S.; Shewach, D. S.; Tang, HY.; Maybaum, J. Résistance to fluorodeoxyuridine-induced DNA damage and cytotoxicity correlates with an elevation of deoxyuridine triphosphatase activity and failure to accumulate deoxyuridine triphosphate. Cancer Res 53:5219-5224; 1993.
34. Wadler, S.; Mao, X.; Bajaj, R.; Hallam, S.; Schwanz, E. L. N-(phosphonacetyl)-L-aspartate synergistically enhances the cytotoxicity of 5-fluorouraciI/interferon-alpha-2a against human colon cancer cell lines. Mol. Pharmacol. 44:1070-1076; 1993.
35. Maybaum, J.; Ullman, B.; Mandel, H. G.; Day, J. L.; Sadee, W. Regulation of RNA- and DNA-directed actions of 5fluoropyrimidines in mouse T-lymphoma (S-49) cells. Cancer Res. 40:4209-4215; 1980.
36. Sobrero, A. F.; Aschele, C.; Guglielmi, A. P.; Mori, A. M.; Melioli, G. G.; Rosso, R.; Bertino, J. R. Synergism and lack of cross-resistance between short-term and continuous exposure to fluorouracil in human colon adenocarcinoma cells. J. Natl. Cancer Inst. 85:1937-1944; 1993.
37. Cadman, E.; Davis, L.; Heimer, R. Enhanced 5-fluorouracil nucleotide formation following methotrexate: Biochemical explanation for drug synergism. Science 205:1135-1137; 1979.
38. Kufe, D. W.; Major, P. P. 5-Fluorouracil incorporation into human breast carcinoma RNA correlates with cytotoxicity. J. Biol. Chem. 256:9802-9805; 1981.
39. Glazer, R. I.; Lloyd, L. S. Association of cell lethality with incorporation of 5-fluorouracil and 5-fluorouridine into nuclear RNA in human colon carcinoma cells in culture. Mol. Pharmacol. 21:468-473; 1982.
40. Laskin, J. D.; Evans, R. M.; Slocum, H. K.; Burke, D.; Hakala, M. T. Basis for natural variation in sensitivity to 5-fluorouracil in mouse and human cells in culture. Cancer Res. 39:383-390; 1979.
41. Patton, J. R. Ribonucleoprotein particle assembly and modification of U2 small nuclear RNA containing 5-fluorouridine. Biochemistry 32:8939-9844; 1993.
42. Radparvar, S.; Houghton, P. J.; Houghton, J. A. Effect of polyglutamylation of 5,10-methylenetetrahydrofolate on the binding of 5-fluoro-2'-deoxyuridylate to thymidylate synthase purified from a human colon adenocarcinoma xenograft. Biochem. Pharmacol. 38:335-342; 1989.
43. Romanini, A.; Lin, J. T.; Niedzwiecki, D.; Bunni, M.; Priest, D. G.; Bertino, J. R. Role of folylpolyglutamates in biochemical modulation of fluoropyrimidines by leucovorin. Cancer Res. 51:789-793; 1991.
44. Boarman, D.; Allegra, C. J. Intracellular metabolism of 5formyl tetrahydrofolate in human breast and colon cell lines. Cancer Res. 52:36-44; 1992.
45. Codacci-Pisanelli, G.; van der Wilt, C. L.; Pinedo, H. M.; Franchi, F.; Noordhuis, P.; Braakhuis, B. J. M.; van Laar, J. A. M.; Peters, G. J. Antitumor activity, toxicity, and inhibition of thymidylate synthase of prolonged administration of 5-fluorouracil in mice. Eur. J. Cancer 31A:1517-1525; 1995.
46. Poorter, R. L.; Peters, G. J.; Bakker, P. M. J.; Taat, C. W.; Diermans-van Leeuwe, D. M. J.; Codacci-Pisanelli, G.; Noordhuis, P.; Ousting, J.; Veenhof, C. H. N. Intermittent continuous infusion of 5-fluorouracil and low dose oral leucovorin in patients with gastrointestinal cancer: Relationship between plasma concentrations and clinical parameters. Eur. J. Cancer 31A:1465-1470; 1995.
47. Leichman, C. G. Prolonged infusion of fluorinated pyrimidines in gastrointestinal malignancies: A reveiw of recent clinical trials. Cancer Invest. 12:166-175; 1994.
48. Berne, M.; Gustavsson, B.; Almersjo, O.; Spears, C. P.; Waldenström, J. Concurrent allopurinol and 5-fluorouracil:5fluoro-2'-deoxyuridylate formation and thymidylate synthase inhibition in rat colon carcinoma in regenerating rat liver. Cancer Chemother. Pharmacol. 20:193; 1987.
49. Chu, E.; Zinn, S.; Boarman, D.; Allegra, C. J. Interaction of interferon and 5-fluorouracil in the H630 human colon carcinoma cell line. Cancer Res. 50:5834-5840; 1990.
50. Swain, S. M.; Lippman, M. E.; Chabner, B. A.; Egan, E. F.; Drake, J. C.; Steinberg, S. M.; Allegra, C. J. Fluorouracil and high-dose leucovorin in previously treated patients with metastatic breast cancer. J. Clin. Oncol. 7:890-899; 1989.
51. Peters, O. J.; van der Wilt, C. L.; van Groeningen, C. J.; Smid, K.; Meijer, S.; Pinedo, H. M. Thymidylate synthase inhibition after administration of fluorouracil with or without leucovorin in colon cancer patients: Implications for treatment with fluorouracil. J. Clin. Oncol. 12:2035-2042; 1994.
52. Alexander, H. R.; Grem, J. L.; Hamilton, J. H.; Pass, H. I.; Hong, M.; Fraker, D. L.; Steinberg, S. M.; McAtee, N.; Allegra, C. J.; Johnston, P. G. Thymidylate synthase protein expression. Association with response to neoadjuvant chemotherapy and resection for locally advanced gastric and gastroesophageal adenocarcinoma. Cancer J. Sci. Am. 1:49-54; 1995.
53. Schuetz, J. D.; Collins, J. M.; Wallace, H. J.; Diasio, R. B. Alteration of the secondary structure of newly synthesized DNA from murine bone marrow cells by 5-fluorouracil. Cancer Res. 46:119-123; 1986.
54. Grem, J. L.; Mulcahy, R. T.; Miller, E. M.; Allegra, C. J.; Fischer, P. H. Interaction of deoxyuridine with fluorouracil and dipyridamole in a human colon cancer cell line. Biochem. Pharmacol. 38:51-59; 1989.
55. Yoshioka, A.; Tanaka, S.; Hiraoka, O.; Koyama, Y.; Hirota, Y.; Ayusawa, D.; Seno, T.; Garret, C.; Wataya, Y. Deoxyribonucleoside triphosphate imbalance. 5-FIuorodeoxyuridineinduced DNA double strand breaks in mouse FM3A cells and the mechanism of cell death. J. Biol. Chem. 262:8235-8241; 1987.
56. Ayusawa, D.; Arai, H.; Wataya, Y.; Sento, T. A specialized form of chromosomal DNA degradation induced by thymidylate stress in mouse FM3A cells. Mutât. Res. 200:221-230; 1988.
57. Canman, C. E.; Tang, H-Y.; Normolle, D. P.; Lawrence, T. S.; Maybaum, J. Variations in patterns of DNA damage induced in human colorectal tumor cells by 5fluorodeoxyuridine: Implications for mechanisms of resistance and cytotoxicity. Proc. Natl. Acad. Sci. USA 89:1047410478;1992.